These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 10079071

  • 1. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, Rettie AE.
    Biochemistry; 1999 Mar 16; 38(11):3285-92. PubMed ID: 10079071
    [Abstract] [Full Text] [Related]

  • 2. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF.
    Arch Biochem Biophys; 1999 Dec 01; 372(1):16-28. PubMed ID: 10562412
    [Abstract] [Full Text] [Related]

  • 3. Arginines 97 and 108 in CYP2C9 are important determinants of the catalytic function.
    Ridderström M, Masimirembwa C, Trump-Kallmeyer S, Ahlefelt M, Otter C, Andersson TB.
    Biochem Biophys Res Commun; 2000 Apr 21; 270(3):983-7. PubMed ID: 10772937
    [Abstract] [Full Text] [Related]

  • 4. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.
    Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE.
    Arch Biochem Biophys; 1996 Sep 15; 333(2):447-58. PubMed ID: 8809086
    [Abstract] [Full Text] [Related]

  • 5. Hydrophobic side chain requirements for lauric acid and progesterone hydroxylation at amino acid 113 in cytochrome P450 2C2, a potential determinant of substrate specificity.
    Straub P, Johnson EF, Kemper B.
    Arch Biochem Biophys; 1993 Nov 01; 306(2):521-7. PubMed ID: 8215458
    [Abstract] [Full Text] [Related]

  • 6. Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase).
    Jones BC, Hawksworth G, Horne VA, Newlands A, Morsman J, Tute MS, Smith DA.
    Drug Metab Dispos; 1996 Feb 01; 24(2):260-6. PubMed ID: 8742240
    [Abstract] [Full Text] [Related]

  • 7. The substrate binding site of human liver cytochrome P450 2C9: an NMR study.
    Poli-Scaife S, Attias R, Dansette PM, Mansuy D.
    Biochemistry; 1997 Oct 21; 36(42):12672-82. PubMed ID: 9335524
    [Abstract] [Full Text] [Related]

  • 8. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ.
    Drug Metab Dispos; 2002 Apr 21; 30(4):385-90. PubMed ID: 11901091
    [Abstract] [Full Text] [Related]

  • 9. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, Sari MA, Johnson EF, Mansuy D.
    Biochemistry; 2004 Dec 14; 43(49):15379-92. PubMed ID: 15581350
    [Abstract] [Full Text] [Related]

  • 10. Identification of residues 286 and 289 as critical for conferring substrate specificity of human CYP2C9 for diclofenac and ibuprofen.
    Klose TS, Ibeanu GC, Ghanayem BI, Pedersen LG, Li L, Hall SD, Goldstein JA.
    Arch Biochem Biophys; 1998 Sep 15; 357(2):240-8. PubMed ID: 9735164
    [Abstract] [Full Text] [Related]

  • 11. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9.
    Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D.
    Biochemistry; 1996 Dec 17; 35(50):16205-12. PubMed ID: 8973193
    [Abstract] [Full Text] [Related]

  • 12. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
    Mosher CM, Hummel MA, Tracy TS, Rettie AE.
    Biochemistry; 2008 Nov 11; 47(45):11725-34. PubMed ID: 18922023
    [Abstract] [Full Text] [Related]

  • 13. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
    Darbyshire JF, Iyer KR, Grogan J, Korzekwa KR, Trager WF.
    Drug Metab Dispos; 1996 Sep 11; 24(9):1038-45. PubMed ID: 8886617
    [Abstract] [Full Text] [Related]

  • 14. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
    Dickmann LJ, Locuson CW, Jones JP, Rettie AE.
    Mol Pharmacol; 2004 Apr 11; 65(4):842-50. PubMed ID: 15044613
    [Abstract] [Full Text] [Related]

  • 15. Site-directed mutagenesis of the putative distal helix of peroxygenase cytochrome P450.
    Matsunaga I, Ueda A, Sumimoto T, Ichihara K, Ayata M, Ogura H.
    Arch Biochem Biophys; 2001 Oct 01; 394(1):45-53. PubMed ID: 11566026
    [Abstract] [Full Text] [Related]

  • 16. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH, Flinois JP, Beaune PH.
    Drug Metab Dispos; 2000 Nov 01; 28(11):1284-90. PubMed ID: 11038154
    [Abstract] [Full Text] [Related]

  • 17. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
    Hutzler JM, Hauer MJ, Tracy TS.
    Drug Metab Dispos; 2001 Jul 01; 29(7):1029-34. PubMed ID: 11408370
    [Abstract] [Full Text] [Related]

  • 18. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C, Witham K, Scott JR, Pearson A, DeVoss JJ, Graham SE, Gillam EM.
    Drug Metab Dispos; 2004 Apr 01; 32(4):431-6. PubMed ID: 15039296
    [Abstract] [Full Text] [Related]

  • 19. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
    Crespi CL, Miller VP.
    Pharmacogenetics; 1997 Jun 01; 7(3):203-10. PubMed ID: 9241660
    [Abstract] [Full Text] [Related]

  • 20. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors.
    Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA.
    Drug Metab Dispos; 2000 Aug 01; 28(8):994-1002. PubMed ID: 10901712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.